Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • AllergoOncology (1)
  • Basic immunology (9)
  • Biologicals (4)
  • Biomarkers (4)
  • Dermatology (1)
  • ENT (1)
  • Immune deficiencies and autoimmunity (1)
  • Microbiome (1)
  • Systems medicine (1)
Poster available until
Poster categories
  • Thematic Poster Session (29)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (14)
  • L-TPS17 (13)
  • L-TPS18 (10)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • x TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • x TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • x TPS48 (5)
  • TPS49 (5)
  • TPS51 (12)
  • TPS52 (14)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (13)
  • TPS56 (16)
  • TPS57 (12)
  • TPS58 (12)
  • TPS59 (13)
  • TPS60 (14)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (8)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
29 results
Thumbnail

D1.342 - Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model

Thumbnail

D1.349 - Age-related fungal molecular clusters revealed by allergen chip assay in Eastern France

Thumbnail

D1.352 - Assessment of the Efficacy of Mepolizumab in Modulating Disease Activity in Eosinophilic Granulomatosis with Polyangiitis: A 12-Month Analysis Evaluating the Birmingham Vasculitis Activity Score

Thumbnail

D1.343 - Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis

Thumbnail

D1.344 - Role of nodular lymphoid hyperplasia as immunologic precursor of IBD development in patients with IBS-like symptoms: an observational, ambispectic, muliticenter study “The NILO study”

Thumbnail

D1.345 - Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study

Thumbnail

D1.346 - Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine

Thumbnail

D1.347 - Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms

Thumbnail

D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

Thumbnail

D1.351 - The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause

Thumbnail

D1.355 - Impact of mesothelin in women with endometriosis

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM